Get started
Author

Aliya F. Gulamhusein

Observed names: A Gulamhusein, A. Gulamhusein, ALIYA GULAMHUSEIN, Aliya F Gulamhusein, Aliya Gulamhusein, Gulamhusein A, Gulamhusein Aliya F, Gulamhusein, Aliya, Gulamhusein, Aliya F.
Observed institutions: Western University, Mount Sinai Hospital, University Health Network, Mayo Clinic, University of Toronto, Toronto Western Hospital, Toronto General Hospital, Princess Margaret Cancer Centre, Salzburger Landeskliniken, Toronto General Hospital Research Institute
ORCID: 0000-0003-4648-4736
Observed ORCID: 0000-0003-4648-4736
OpenAlex ID: A5025186476
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
2016 · Sun-Gou Ji, The International PSC Study Group, et al. · Nature Genetics · 358
PDF
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
2019 · Aliya F. Gulamhusein, Gideon M. Hirschfield · Nature Reviews Gastroenterology & Hepatology · 308
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
2019 · Michael Trauner, Aliya Gulamhusein, et al. · Hepatology · 261
PDF
Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver
2024 · Tallulah S. Andrews, Diana Nakib, et al. · Journal of Hepatology · 190
PDF
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
2020 · Carla F. Murillo Perez, Maren H. Harms, et al. · The American Journal of Gastroenterology · 183
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
2023 · Gideon M. Hirschfield, Mitchell L. Shiffman, et al. · Hepatology · 125
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
2022 · Christophe Corpechot, Fabrice Carrat, et al. · Journal of Hepatology · 122
PDF
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
2019 · Carla F. Murillo Perez, Gideon M. Hirschfield, et al. · Alimentary Pharmacology & Therapeutics · 117
PDF
Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD
2016 · Aliya F Gulamhusein, John E Eaton, et al. · The American Journal of Gastroenterology · 116
5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations
2012 · Geoffrey C Nguyen, Aliya Gulamhusein, et al. · The American Journal of Gastroenterology · 113
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
2022 · C. Fiorella Murillo Perez, Holly Fisher, et al. · Gastroenterology · 106
PDF
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
2023 · Christophe Corpechot, Sara Lemoinne, et al. · Hepatology · 90
Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history
2017 · Carla F. Murillo Perez, Jorn C. Goet, et al. · Hepatology · 90
PDF
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
2019 · Angela C. Cheung, Willem J. Lammers, et al. · Clinical Gastroenterology and Hepatology · 83
PDF
Genome-Wide Association Studies in Primary Biliary Cirrhosis
2015 · Aliya Gulamhusein, Brian Juran, et al. · Seminars in Liver Disease · 69
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
2022 · Jun Xu, Ya Wang, et al. · Hepatology · 59
Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
2020 · Surain B. Roberts, Marwa Ismail, et al. · Hepatology Communications · 57
PDF
Autoimmune hepatitis: Current and future therapeutic options
2019 · Iliana Doycheva, Kymberly D. Watt, et al. · Liver International · 55
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study
2022 · Thijmen Visseren, Nicole S. Erler, et al. · JHEP Reports · 48
Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps
2019 · Liselot W. van Erp, Morven Cunningham, et al. · Liver International · 47
Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study
2024 · Christina G. Plagiannakos, Gideon M. Hirschfield, et al. · Journal of Hepatology · 44
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
2022 · Michael Trauner, Christopher L. Bowlus, et al. · Clinical Gastroenterology and Hepatology · 43
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
2024 · Laurent Lam, Pierre-Antoine Soret, et al. · Clinical Gastroenterology and Hepatology · 41
A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.
2019 · Fernanda Q Onofrio, Gideon M Hirschfield, et al. · PubMed · 41
Current Use of Hearts From Hepatitis C Viremic Donors
2018 · Yasbanoo Moayedi, Chun Po S. Fan, et al. · Circulation Heart Failure · 40
Works count: 175
Citation count: 3,402
H-index: 27
I10-index: 50
Year
Topic
Type